Management of pulmonary tuberculosis on the background of intestinal malabsorption syndrome


OBJECTIVE. To investigate the frequency of malabsorption in newly diagnosed sensitive pulmonary tuberculosis (TB) and to establish the effectiveness of treatment correction in these patients.

MATERIALS AND METHODS. In the first stage of the study, 73 patients with new drug-susceptible TB underwent lactulose-mannitol test. Individuals with intestinal permeability index <3 were selected and divided into main group which received injectable forms of isoniazid, rifampicin, ethambutol and oral pyrazinamide and control group which received standard treatment orally.

RESULTS. Bacterial excretion stopped in 88.2 % of patients in the main group and in only 61.5 % of patients in the control group. In 46.1 % of cases in the control group treatment failure was diagnosed. The frequency of positive radiological dynamics at the end of the intensive phase of treatment was 64.7 % in the main group versus 30.8 % in the control group. The total efficacy of treatment at the end of the main course of chemotherapy was 88.2 % in the main group against 53.9 % in the control group (p <0.05).

CONCLUSIONS. Malabsorption, which requires correction of treatment, occurs in about one-fifth of patients with new TB. Usage of injectable anti-TB drugs in such patients increases the effectiveness of treatment by 34 % (p <0.05).

Keywords: tuberculosis, malabsorption, injectable anti-tuberculosis drugs.


Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: WHO; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Global tuberculosis report (2020). Geneva: WHO; 2020.

Walton K.D., Freddo A.M., Sha Wang, Gumucio D.L. Generation of intestinal surface: an absorbing tale. Development. 2016; 143 (13): 2261-2272. doi: 10.1242/dev.135400.

Gurumurthy P., Ramachandran G., Hemanth Kumar A. et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004; 48: 4473-4475.

Tian J.H., Lu Z.X., Bachmann M.O., Song F.J. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int. J. Tuberc. Lung Dis. 2014 Sep; 18 (9): 1092-8. doi: 10.5588/ijtld.13.0867. PMID: 25189558.

Katiyar S., Bihari S., Prakash S. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2008; 12: 139-145.

Um S.W., Lee S.W., Kwon S.Y., Yoon H.I., Park K.U., Song J., Lee C.T., Lee J.H. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int. J. Tuberc. Lung Dis. 2007 Sep; 11 (9): 972-8. PMID: 17705974.

Diacon A.H., Patientia R.F., Venter A., van Helden P.D., Smith P.J., McIlleron H., Maritz J.S., Donald P.R. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 2007 Aug; 51 (8): 2994-6. doi: 10.1128/AAC.01474-06. Epub 2007 May 21. PMID: 17517849; PMCID: PMC1932511.

Burhan E., Ruesen C., Ruslami R., Ginanjar A., Mangunnegoro H., Ascobat P., Donders R., van Crevel R., Aarnoutse R. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 2013 Aug; 57 (8): 3614-9. doi: 10.1128/AAC.02468-12. Epub 2013 May 20. PMID: 23689725; PMCID: PMC3719785.

Zakharov A.V., Kibrik B.S. Increasing the effectiveness of chemotherapy for drug-resistant tuberculosis in the experiment using nanosilver. Tuberculosis and Lung Disease. 2015; 7: 47-48.

Gerasimova N.A., Polyakova S.O. Infusion of new methods of the introduction of anti-tuberculosis drugs on their tolerance in case of illnesses on the first diagnostics of destructive tuberculosis of the lung. Ukrainian Medical Almanac. 2013; 1: 55-56.

Gavriliev S.S., Vinokurova M.K., Pavlova E.S., Yakovleva L.P., Illarionova T.S. Сoncept of directed pharmacokinetics of antituberculosis drugs. Advances in Modern Natural Science. 2009; 11: 79-81.

Kuzhko M.M., Klimenko M.T., Gulchuk N.M. Possibility of pharmacotherapy for tuberculosis legen. Tuberculosis, lung diseases, HIV-infection. 2012; 4: 57-64.

Pinheiro V.G., Ramos L.M., Monteiro H.S., Barroso E.C., Bushen O.Y., Facanha M.C., Peloquin C.A., Guerrant R.L., Lima A.A. Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz. J. Infect. Dis. 2006 Dec; 10 (6): 374-9. doi: 10.1590/s1413-86702006000600003. PMID: 17420908.

Bento J., Duarte R., Brito M., Leite S., Lobato M., Caldeira Mdo C., Carvalho A. Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis. BMJ Case Rep. 2010 Sep 29; 2010: bcr1220092554. doi: 10.1136/bcr.12.2009.2554. PMID: 22778380; PMCID: PMC3028077.

How to Cite
Todoriko, L., & Pidverbetska, O. (2021). Management of pulmonary tuberculosis on the background of intestinal malabsorption syndrome. Infusion & Chemotherapy, (2), 39-43.

Author Biographies

L.D. Todoriko, Bukovinian State Medical University, Chernivtsi, Ukraine

Todoriko Lilіa Dmytrivna
Нead of Department of Phthisiology and Pulmonology.
MD, professor.
2, Theatralna sq., Chernivtsi, 58002, Ukraine.

O.V. Pidverbetska, Bukovinian State Medical University, Chernivtsi, Ukraine

Pidverbetska Olena Valeriivna
Assistant of the Department of Phthisiology and Pulmonology.
2, Theatralna sq., Chernivtsi, 58002, Ukraine.